Kayo Fujita1, Masayuki Kaneko2, Mamoru Narukawa2. 1. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan. kayo.fujita@pfizer.com. 2. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Abstract
BACKGROUND AND OBJECTIVE: Several systematic reviews and meta-analyses have been conducted including an analysis to investigate the difference between ethnic groups in the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. This study assessed the factors related to the glucose-lowering efficacy and explored potential differences among ethnicities; in particular, Japanese subjects were dealt separately from other Asian subjects. METHODS: A systematic literature search was conducted using the MEDLINE, EMBASE, Cochrane Central Register, Japan Medical Abstracts Society, and ClinicalTrials.gov databases. Electronically searchable study results from the US/EU/Japanese regulatory approval reviews were also used. The weighted mean difference (WMD) for glycosylated hemoglobin (HbA1c) change from baseline in DPP-4 inhibitors compared with placebo was calculated. Heterogeneity was assessed by using the Q statistic and I 2 statistic. Univariate and multivariate meta-regression analyses were performed. RESULTS: The literature search identified 79 studies with 91 arms and 25,095 patients. The WMD in the change from baseline of HbA1c between the DPP-4 inhibitor group and placebo group was -0.695% (95% confidence interval -0.734 to -0.656) with considerable heterogeneity (I 2 = 69.7%). In univariate meta-regression, factors including study duration, percentage of males, age, duration of diabetes mellitus, baseline HbA1c values, body mass index, body weight, and percentage of Asian subjects showed associations with the glucose-lowering efficacy. Additionally, studies in Asian subjects, studies in Japanese subjects, and studies conducted in Japan showed relations when three classifications regarding ethnicity and study regions were applied. In multivariate meta-regression, studies in Japanese subjects/studies conducted in Japan as well as the baseline HbA1c values were identified as influencing factors. CONCLUSION: These identified factors-Japanese subjects/studies conducted in Japan and the baseline HbA1c values-should be taken into account when planning and conducting future clinical studies.
BACKGROUND AND OBJECTIVE: Several systematic reviews and meta-analyses have been conducted including an analysis to investigate the difference between ethnic groups in the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. This study assessed the factors related to the glucose-lowering efficacy and explored potential differences among ethnicities; in particular, Japanese subjects were dealt separately from other Asian subjects. METHODS: A systematic literature search was conducted using the MEDLINE, EMBASE, Cochrane Central Register, Japan Medical Abstracts Society, and ClinicalTrials.gov databases. Electronically searchable study results from the US/EU/Japanese regulatory approval reviews were also used. The weighted mean difference (WMD) for glycosylated hemoglobin (HbA1c) change from baseline in DPP-4 inhibitors compared with placebo was calculated. Heterogeneity was assessed by using the Q statistic and I 2 statistic. Univariate and multivariate meta-regression analyses were performed. RESULTS: The literature search identified 79 studies with 91 arms and 25,095 patients. The WMD in the change from baseline of HbA1c between the DPP-4 inhibitor group and placebo group was -0.695% (95% confidence interval -0.734 to -0.656) with considerable heterogeneity (I 2 = 69.7%). In univariate meta-regression, factors including study duration, percentage of males, age, duration of diabetes mellitus, baseline HbA1c values, body mass index, body weight, and percentage of Asian subjects showed associations with the glucose-lowering efficacy. Additionally, studies in Asian subjects, studies in Japanese subjects, and studies conducted in Japan showed relations when three classifications regarding ethnicity and study regions were applied. In multivariate meta-regression, studies in Japanese subjects/studies conducted in Japan as well as the baseline HbA1c values were identified as influencing factors. CONCLUSION: These identified factors-Japanese subjects/studies conducted in Japan and the baseline HbA1c values-should be taken into account when planning and conducting future clinical studies.
Authors: Robert G Moses; Elizabeth Round; Yue Shentu; Gregory T Golm; Edward A O'neill; Ira Gantz; Samuel S Engel; Keith D Kaufman; Barry J Goldstein Journal: J Diabetes Date: 2016-02-03 Impact factor: 4.006
Authors: F J Lavalle-González; A Januszewicz; J Davidson; C Tong; R Qiu; W Canovatchel; G Meininger Journal: Diabetologia Date: 2013-09-13 Impact factor: 10.122
Authors: Ralph A DeFronzo; Miguel N Hissa; Alan J Garber; Jorge Luiz Gross; Raina Yuyan Duan; Shoba Ravichandran; Roland S Chen Journal: Diabetes Care Date: 2009-05-28 Impact factor: 19.112